# DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

> **NCT00889408** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 25 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** DT2219ARL

## Key facts

- **NCT ID:** NCT00889408
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2014-07-21
- **Final completion:** 2014-07-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889408, "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00889408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*